LivaNova PLC - Asset Resilience Ratio
LivaNova PLC (LIVN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LivaNova PLC PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2022)
This chart shows how LivaNova PLC's Asset Resilience Ratio has changed over time. See LivaNova PLC balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down LivaNova PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is LivaNova PLC worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $42.00K | 0.0% |
| Total Liquid Assets | $42.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LivaNova PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LivaNova PLC Industry Peers by Asset Resilience Ratio
Compare LivaNova PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic PLC
XETRA:2M6 |
Medical Devices | 7.91% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
Aroa Biosurgery Ltd
AU:ARX |
Medical Devices | 12.13% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Bluelinea SA
PA:ALBLU |
Medical Devices | 1.07% |
|
elexxion AG
XETRA:E8X |
Medical Devices | 5.50% |
Annual Asset Resilience Ratio for LivaNova PLC (1998–2022)
The table below shows the annual Asset Resilience Ratio data for LivaNova PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $-34.00K | $2.29 Billion | 0.00pp |
| 2021-12-31 | 0.00% | $-2.00K | $2.20 Billion | -1.30pp |
| 2020-12-31 | 1.30% | $31.09 Million | $2.40 Billion | +1.19pp |
| 2018-12-31 | 0.10% | $2.65 Million | $2.55 Billion | -0.01pp |
| 2017-12-31 | 0.12% | $2.94 Million | $2.50 Billion | +0.12pp |
| 2016-12-31 | 0.00% | $-8.00K | $2.34 Billion | -0.27pp |
| 2015-12-31 | 0.27% | $7.00 Million | $2.56 Billion | -8.23pp |
| 2014-12-31 | 8.51% | $25.03 Million | $294.19 Million | 0.00pp |
| 2013-12-31 | 8.51% | $25.03 Million | $294.19 Million | +2.79pp |
| 2012-12-31 | 5.72% | $15.10 Million | $264.04 Million | -1.36pp |
| 2011-12-31 | 7.08% | $15.00 Million | $211.91 Million | +6.60pp |
| 2009-12-31 | 0.48% | $1.00 Million | $207.47 Million | -0.20pp |
| 2008-12-31 | 0.68% | $1.00 Million | $146.21 Million | -0.27pp |
| 2007-12-31 | 0.95% | $1.00 Million | $105.19 Million | +0.22pp |
| 2006-12-31 | 0.73% | $1.00 Million | $136.23 Million | +0.08pp |
| 2005-12-31 | 0.66% | $1.00 Million | $152.30 Million | -22.41pp |
| 2004-12-31 | 23.06% | $22.80 Million | $98.86 Million | +22.98pp |
| 2000-12-31 | 0.08% | $57.54K | $67.99 Million | -3.80pp |
| 1999-12-31 | 3.89% | $1.56 Million | $40.00 Million | -44.35pp |
| 1998-12-31 | 48.24% | $19.20 Million | $39.80 Million | -- |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. … Read more